Gitman Paul 4
4 · BIOSPECIFICS TECHNOLOGIES CORP · Filed Dec 2, 2020
Insider Transaction Report
Form 4
Gitman Paul
Director
Transactions
- Disposition to Issuer
Common Stock, $0.001 par value
2020-12-02−1,726→ 0 total - Disposition to Issuer
Common Stock, $0.001 par value
2020-12-02−16,890→ 1,726 total
Footnotes (2)
- [F1]Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 16,890 shares of common stock were exchanged for a cash payment of $1,494,765.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person.
- [F2]Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were cancelled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).